Predictors of response to bevacizumab monotherapy in polypoidal choroidal vasculopathy: a 12-month retrospective study
Approximately half of PCV eyes demonstrated a favorable response to bevacizumab monotherapy. Baseline SRF height and SFCT were significant predictors of treatment response. Early assessment after three monthly bevacizumab injections allowed for the differentiation between relatively mild and a more severe disease requiring more frequent and sustained anti-VEGF injections. Switching of anti-VEGFs was associated with improved outcomes in poor responders.
Authors
- Nopasak Phasukkijwatana (ORCID: https://orcid.org/0000-0002-2317-771X)
- Nuttawut Rodanant
- Chinnapat Montrisuksirikun (ORCID: https://orcid.org/0000-0002-8383-7660)
- Supredee Pongrujikorn (ORCID: https://orcid.org/0009-0001-7650-4219)
- Supalert Prakhunhungsit (ORCID: https://orcid.org/0000-0002-0211-113X)
- Nida Wongchaisuwat
- Somanus Thoongsuwan
Institutions
- Siriraj Hospital (TH)
- Mahidol University (TH)
Publication Details
- Journal
- International Journal of Retina and Vitreous
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1186/s40942-025-00795-x
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00